Abiopharma

🔍 White Matthew J (Executive)

Company: LINDE PLC (LIN)

Report Date: 2026-03-09

Detailed Transactions and Holdings:

• Acquired 8,136 shares of Ordinary Shares (Direct)
  Date: 2026-03-09 | Code: M | equity_swap_involved: 0 | shares_owned_after: 83,785.80 | transaction_form_type: 4 | Footnotes: F1
• Sold 3,771 shares of Ordinary Shares at $484.74 per share (Direct)
  Date: 2026-03-09 | Code: F | equity_swap_involved: 0 | shares_owned_after: 80,014.80 | transaction_form_type: 4 | Footnotes: F2
• Acquired 2,870 shares of Ordinary Shares (Direct)
  Date: 2026-03-09 | Code: M | equity_swap_involved: 0 | shares_owned_after: 82,884.80 | transaction_form_type: 4 | Footnotes: F1
• Sold 1,330 shares of Ordinary Shares at $484.74 per share (Direct)
  Date: 2026-03-09 | Code: F | equity_swap_involved: 0 | shares_owned_after: 81,554.80 | transaction_form_type: 4 | Footnotes: F2
• Acquired 2,870 shares of Ordinary Shares (Direct)
  Date: 2026-03-09 | Code: M | equity_swap_involved: 0 | shares_owned_after: 84,424.80 | transaction_form_type: 4 | Footnotes: F3
• Sold 1,330 shares of Ordinary Shares at $484.74 per share (Direct)
  Date: 2026-03-09 | Code: F | equity_swap_involved: 0 | shares_owned_after: 83,094.80 | transaction_form_type: 4 | Footnotes: F2
• Holds 0 shares of Ordinary Shares (Direct)
  Date: 2026-03-09 | Code: H | nature_of_ownership: 401(k) | shares_owned_after: 3,096.22
• Acquired 8,136 shares of Performance Share Units (ROC) (Derivative)
  Date: 2026-03-09 | Code: A | equity_swap_involved: 0 | shares_owned_after: 8,136.00 | transaction_form_type: 4 | Footnotes: F4, F5, F5
• Sold 8,136 shares of Performance Share Units (ROC) (Derivative)
  Date: 2026-03-09 | Code: M | equity_swap_involved: 0 | transaction_form_type: 4 | Footnotes: F4, F5, F5
• Acquired 2,870 shares of Performance Share Units (RTSR) (Derivative)
  Date: 2026-03-09 | Code: A | equity_swap_involved: 0 | shares_owned_after: 2,870.00 | transaction_form_type: 4 | Footnotes: F4, F6, F6
• Sold 2,870 shares of Performance Share Units (RTSR) (Derivative)
  Date: 2026-03-09 | Code: M | equity_swap_involved: 0 | transaction_form_type: 4 | Footnotes: F4, F6, F6
• Acquired 3,098 shares of Restricted Stock Units (Derivative)
  Date: 2026-03-09 | Code: A | equity_swap_involved: 0 | shares_owned_after: 3,098.00 | transaction_form_type: 4 | Footnotes: F4, F7, F7
• Sold 2,870 shares of Restricted Stock Units (Derivative)
  Date: 2026-03-09 | Code: M | equity_swap_involved: 0 | transaction_form_type: 4 | Footnotes: F4, F10, F10
• Acquired 25,259 shares of Stock Options (right to buy) at $483.62 per share (Derivative)
  Date: 2026-03-09 | Code: A | Expires: 2036-03-09 | equity_swap_involved: 0 | shares_owned_after: 25,259.00 | transaction_form_type: 4 | Footnotes: F11
• Holds 2,728 shares of Restricted Stock Units (Derivative)
  Date: 2026-03-09 | Code: H | shares_owned_after: 2,728.00 | Footnotes: F4, F8, F8
• Holds 2,625 shares of Restricted Stock Units (Derivative)
  Date: 2026-03-09 | Code: H | shares_owned_after: 2,625.00 | Footnotes: F4, F9, F9
• Holds 19,156 shares of Stock Options (right to buy) at $468.77 per share (Derivative)
  Date: 2026-03-09 | Code: H | Expires: 2035-03-07 | shares_owned_after: 19,156.00 | Footnotes: F12
• Holds 17,015 shares of Stock Options (right to buy) at $465.29 per share (Derivative)
  Date: 2026-03-09 | Code: H | Expires: 2034-03-07 | shares_owned_after: 17,015.00 | Footnotes: F13
• Holds 18,970 shares of Stock Options (right to buy) at $354.14 per share (Derivative)
  Date: 2026-03-09 | Code: H | Expires: 2033-03-07 | shares_owned_after: 18,970.00 | Footnotes: F14
• Holds 22,535 shares of Stock Options (right to buy) at $270.99 per share (Derivative)
  Date: 2026-03-09 | Code: H | Expires: 2032-03-07 | shares_owned_after: 22,535.00 | Footnotes: F15
• Holds 34,320 shares of Stock Options (right to buy) at $253.68 per share (Derivative)
  Date: 2026-03-09 | Code: H | Expires: 2031-03-08 | shares_owned_after: 34,320.00 | Footnotes: F15
• Holds 43,695 shares of Stock Options (right to buy) at $173.13 per share (Derivative)
  Date: 2026-03-09 | Code: H | Expires: 2030-03-09 | shares_owned_after: 43,695.00 | Footnotes: F16
• Holds 47,020 shares of Stock Options (right to buy) at $176.63 per share (Derivative)
  Date: 2026-03-09 | Code: H | Expires: 2029-03-20 | shares_owned_after: 47,020.00 | Footnotes: F17
• Holds 64,665 shares of Stock Options (right to buy) at $154.0 per share (Derivative)
  Date: 2026-03-09 | Code: H | Expires: 2028-02-27 | shares_owned_after: 64,665.00 | Footnotes: F17
• Holds 72,795 shares of Stock Options (right to buy) at $118.71 per share (Derivative)
  Date: 2026-03-09 | Code: H | Expires: 2027-02-28 | shares_owned_after: 72,795.00 | Footnotes: F17
• Holds 1,542 shares of Deferred Stock Units (Derivative)
  Date: 2026-03-09 | Code: H | shares_owned_after: 1,541.95 | Footnotes: F4, F18, F18

Footnotes:

• F1: Ordinary shares acquired pursuant to the payout of a performance share unit ("PSU") grant made on March 7, 2023.
• F2: Ordinary shares withheld from the payout to cover tax withholdings.
• F3: Ordinary shares acquired pursuant to the payout of a restricted stock unit grant made on March 7, 2023.
• F4: Conversion to Linde plc Ordinary Shares is on a one-for-one basis.
• F5: The PSU paid out on March 9, 2026, and the number of shares awarded and paid out was determined based upon the average annual return on capital ("ROC") of Linde plc from 2023-2025 measured against ROC goals set by the Human Capital Committee of the Board of Directors when the PSU was granted on March 7, 2023.
• F6: The PSU paid out on March 9, 2026, and the number of shares awarded and paid out was determined based upon the relative total shareholder return ("RTSR") of Linde plc from 2023-2025 measured against TSR goals set by the Human Capital Committee of the Board of Directors when the PSU was granted on March 7, 2023.
• F7: Restricted Stock Units that will vest in full and payout on or about March 9, 2029 in Linde plc Ordinary Shares on a one-for-one basis.
• F8: Restricted Stock Units that will vest in full and payout on or about March 7, 2028 in Linde plc Ordinary Shares on a one-for-one basis.
• F9: Restricted Stock Units that will vest in full and payout on or about March 7, 2027 in Linde plc Ordinary Shares on a one-for-one basis.
• F10: Restricted Stock Units that vested in full and paid out on March 9, 2026 in Linde plc Ordinary Shares on a one-for-one basis.
• F11: This option vests over three years in three consecutive equal annual installments beginning on March 9, 2027.
• F12: This option vests over three years in three consecutive equal annual installments beginning on March 7, 2026.
• F13: This option vests over three years in three consecutive equal annual installments beginning on March 7, 2025.
• F14: This option vests over three years in three consecutive equal annual installments beginning on March 7, 2024.
• F15: This option vests over three years in three consecutive equal annual installments beginning on March 7, 2023.
• F16: This option vests over three years in three consecutive equal annual installments beginning on March 9, 2021.
• F17: This option vested in full and became exercisable in three (3) equal annual installments beginning on the first anniversary of the date of grant.
• F18: Deferred stock units acquired under the Linde Compensation Deferral Plan ("Plan"). The deferred stock units will payout in Linde plc Ordinary Share on a one-for-one basis in accordance with the Plan.